Phase I/II Study of the Human Anti-Mesothelin Antibody Drug Conjugate Anetumab Ravtansine (AR), Combined With the PD-L1 Inhibitor Atezolizumab in Non-Small Cell Lung Cancer
Status: Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 16 Sep 2019
Price : $35 *
At a glance
- Drugs Anetumab ravtansine (Primary) ; Atezolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 11 Sep 2019 Status changed from suspended to active, no longer recruiting.
- 29 Aug 2019 Status changed from recruiting to suspended due to slow accrual.
- 31 Aug 2018 Biomarkers information updated